What is the current market size?

The global monkeypox virus tests market size was valued at approximately USD 1.2 billion in 2023, driven by urgent diagnostic demand during outbreaks.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2031, with rapid adoption of PCR-based and rapid antigen tests.

What are the key drivers?

Key drivers include rising global outbreaks, government funding for infectious disease surveillance, and advancements in rapid diagnostic technologies.

What challenges hinder growth?

Challenges include limited test specificity for monkeypox variants, supply chain disruptions, and high costs of advanced molecular testing platforms.

Which regions lead the market?

North America dominates the market, followed by Europe, due to high healthcare spending and frequent monkeypox cases. Asia-Pacific shows fastest growth.

Who are the top companies?

Leading players include Thermo Fisher Scientific, Becton Dickinson, QIAGEN, and BioMérieux, leveraging their diagnostic expertise and global distribution networks.

What future opportunities exist?

Opportunities lie in multiplex testing for co-infections, AI-driven diagnostic tools, and expanding access in low-resource regions through portable test formats.

How does technology impact the market?

PCR and CRISPR-based technologies drive accuracy, while lateral flow assays enhance accessibility, shaping the market’s innovation trajectory.

What is the regulatory landscape?

Regulators like FDA and EMA prioritize emergency use authorizations for rapid tests, while WHO guidelines standardize global diagnostic protocols and quality assurance.

monkeypox virus tests Market Growth Drivers & Forecast 2033

monkeypox virus tests by Application (Hospitals & Clinics, Diagnostic Laboratories, Others), by Types (Polymerase Chain Reaction (PCR), Lateral Flow Assay (LFA), Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 25%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 25%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

monkeypox virus tests Market Size | CAGR 25 Forecast 2033

monkeypox virus tests Market Growth Drivers & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 25%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 25%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

monkeypox virus tests Market Overview

The monkeypox virus tests market encompasses diagnostic solutions designed to detect Orthopoxvirus infections, driven by global health priorities and outbreak preparedness. As the monkeypox virus tests market size expands, stakeholders are increasingly focused on market forecast trends and industry expansion opportunities. The market, valued at USD 650 million in 2025, is projected to grow at a CAGR of 10–12% through 2033, fueled by rising outbreak threats, advancements in molecular testing, and regulatory frameworks prioritizing rapid diagnostics. Key growth outlook factors include heightened surveillance in high-risk regions and the adoption of at-home self-testing kits.

Loading chart…

The market is shaped by technology shifts toward faster, more accurate diagnostics—such as isothermal amplification—and regulatory changes mandating test validation for global distribution. Competitive intensity is rising, with niche players innovating point-of-care solutions while large diagnostics firms scale production. North America remains the largest region due to advanced healthcare infrastructure, while Asia-Pacific is the fastest-growing, driven by expanding diagnostic networks and improving reimbursement policies. Strategic partnerships and R&D investments will be critical to addressing supply-chain bottlenecks and ensuring equitable test access globally.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	894.07 million
Growth rate	CAGR of 25% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Aegis Sciences Corp.; Laboratory Corp. of America Holdings; Quest Diagnostics, Inc.; Sonic Healthcare Ltd.; QIAGEN; Mayo Clinic Laboratories; Chembio Diagnostics, Inc.; Sonora Quest Laboratories; Thermo Fisher Scientific; BD
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising monkeypox virus tests market demand due to recurring outbreaks and heightened public health vigilance is accelerating adoption of diagnostic solutions, particularly in high-risk regions such as North America and Europe. _Early detection mandates_ by regulatory bodies are further fueling uptake.

Advancements in _rapid antigen testing_ and multiplex PCR technologies are enhancing diagnostic accuracy and speed, positioning the monkeypox virus tests market size for robust growth forecast of 12–15% CAGR through 2030, driven by healthcare providers’ preference for efficient testing workflows.

Restraints2 items

_High costs_ of specialized molecular testing kits and limited reimbursement policies in emerging economies may constrain market penetration despite rising case counts.

Regulatory bottlenecks in test approval and standardization across jurisdictions could delay product commercialization, creating friction in market scalability.

Opportunities2 items

Expansion into _underserved geographies_ like Latin America and Southeast Asia, where healthcare infrastructure is improving and diagnostic awareness is growing, presents untapped revenue streams for market players.

Strategic collaborations between diagnostic firms and government agencies for _bulk procurement contracts_ offer a pathway to secure long-term market share amid fluctuating outbreak cycles.

Challenges2 items

Supply chain vulnerabilities for critical reagents and equipment, exacerbated by global macroeconomic instability, risk disrupting test production and distribution timelines.

_Price competition_ from generic test manufacturers is intensifying, pressuring profit margins for premium players in the monkeypox virus tests market as payers prioritize cost efficiency.

Market Segmentation

Loading chart…

The monkeypox virus tests segmentation by application reveals two primary drivers: diagnostic testing and surveillance & monitoring. Diagnostic testing constitutes the largest share, driven by clinical demand for accurate patient diagnosis, especially in outbreaks. Public health agencies and hospitals prioritize this segment, contributing significantly to market growth. Conversely, surveillance & monitoring focuses on tracking transmission patterns and identifying hotspots, primarily utilized by governmental health bodies. This segment relies on large-scale testing programs and environmental sampling. Together, these applications define the market’s scope, with diagnostic testing accounting for ~65% of the market size due to its critical role in clinical decision-making.

The types segment of the monkeypox virus tests market is divided into PCR-based tests and antigen-based tests, each with distinct technical and operational roles. PCR-based tests dominate due to their high specificity and sensitivity, making them the gold standard for confirming monkeypox cases. Their adoption is concentrated in centralized laboratories, limiting speed but ensuring accuracy. Antigen-based tests, while less sensitive, enable rapid point-of-care diagnostics, catering to urgent clinical needs and resource-constrained settings. This segment is growing due to its simplicity and cost-effectiveness. PCR tests currently hold ~70% of the types market share, reflecting their entrenched use in diagnostic protocols. Antigen-based tests, however, are gaining traction in outbreak scenarios requiring swift triage.

monkeypox virus tests Segmentation Breakdown8 items

Application

Hospitals & Clinics

Diagnostic Laboratories

Others

Types

Polymerase Chain Reaction (PCR)

Lateral Flow Assay (LFA)

Others

Regional Insights

Loading chart…

North America dominates the monkeypox virus tests market, accounting for 45% of global demand, driven by rapid adoption of advanced diagnostics, robust healthcare infrastructure, and proactive government policies. The region’s mature ecosystem, supported by high R&D investments and strategic collaborations between public and private entities, ensures swift response to outbreaks. The U.S. leads with FDA-approved rapid tests and widespread PCR testing infrastructure, while Canada benefits from cross-border supply chain efficiencies.

Europe follows as the second-largest market (30%), with Germany, France, and the UK leveraging EU-wide initiatives and harmonized regulatory frameworks to accelerate test deployment. Aging populations and heightened awareness post-2022 outbreaks have spurred adoption. The region’s growth hinges on public funding for diagnostic scale-up and cross-border data-sharing platforms like the ECDC, which enhance surveillance capabilities.

Asia Pacific is the fastest-growing region, expanding at a CAGR of 12% through 2027, fueled by improving healthcare access in emerging economies (e.g., India, Indonesia) and increased investments in molecular testing. Japan and South Korea lead in adopting AI-driven diagnostics, while Southeast Asia’s growth is supported by regional partnerships and WHO funding. However, disparities in infrastructure and affordability remain challenges.

Latin America (7%) and the Middle East & Africa (3%) face fragmented adoption due to underdeveloped healthcare systems but show potential through targeted investments. Brazil and Mexico are prioritizing monkeypox testing amid overlapping health crises, while South Africa and the UAE are expanding diagnostic labs with international aid. Regional disparities underscore the need for localized monkeypox virus tests market growth strategies.

Competitive Landscape

The monkeypox virus tests competitive landscape remains moderately consolidated, with a mix of global diagnostic firms and regionally focused laboratories. Key players leverage regulatory approvals and CLIA certification as critical differentiators, while pricing strategies vary between high-margin PCR-based solutions and lower-cost antigen rapid tests. Distribution channels reflect this duality, with centralized labs dominating complex testing and decentralized point-of-care providers targeting urgent care settings. Innovation cycles emphasize multiplex PCR integration to address cross-infection concerns, though supply chain disruptions for reagents continue to impact time-to-market for new entrants.

Strategic priorities center on expanding test menu breadth through partnerships with biotechnology firms, alongside geographic expansion via lab network acquisitions. Customization capabilities for public health agencies and hospitals emerge as a key service model differentiator. However, margin pressures intensify as payers push for price parity between monkeypox and other infectious disease testing protocols. Regulatory harmonization efforts across the EU and U.S. create both opportunities and barriers, requiring firms to balance compliance costs against market access advantages.

QIAGEN: Innovation pipeline for multiplex PCR test integration

Thermo Fisher Scientific: OEM tie-ups to expand diagnostic reach

BD: Vertical integration for rapid antigen solution production

Mayo Clinic Laboratories: Localization through hospital network partnerships

Chembio Diagnostics, Inc.: Cost advantages via point-of-care lateral flow assays

Sonic Healthcare Ltd.: Global expansion using standardized lab accreditations

Key monkeypox virus tests Companies10 items

Aegis Sciences Corp.

Laboratory Corp. of America Holdings

Quest Diagnostics, Inc.

Sonic Healthcare Ltd.

QIAGEN

Mayo Clinic Laboratories

Chembio Diagnostics, Inc.

Sonora Quest Laboratories

Thermo Fisher Scientific

Market Ecosystem

The monkeypox virus tests ecosystem spans upstream innovation, midstream production, and downstream application. Upstream suppliers develop foundational technologies and raw materials, while midstream manufacturers and integrators transform these inputs into diagnostic solutions. Downstream distribution channels and end users drive market demand, with regulatory bodies shaping compliance standards across the value chain.

Raw material/component suppliers — Provide reagents, enzymes, and consumables for test kit production

Technology providers — License molecular detection platforms (e.g., PCR, CRISPR-based systems)

Test manufacturers — Produce in vitro diagnostic kits for clinical and point-of-care settings

System integrators — Combine hardware, software, and assays into validated diagnostic workflows

Distributors/channel partners — Supply tests to healthcare facilities and public health agencies

End users (healthcare providers) — Deploy tests for patient diagnosis and outbreak monitoring

Regulators/standards bodies — Approve tests via emergency use authorizations or full regulatory pathways

Value flows through the monkeypox virus tests ecosystem via technology licensing, manufacturing scale, and regulatory compliance. Bottlenecks emerge at regulatory approval stages and raw material sourcing, while integrators control interoperability requirements for multi-vendor systems. Regional ecosystems differ in dependency on local manufacturing capacity and public health procurement policies, with switching costs for diagnostic platforms influenced by training and validation protocols.

Recent Industry Insights

The monkeypox virus tests industry trends have evolved significantly over the past 18 months, driven by surges in outbreaks and advancements in diagnostic technologies. Key players such as Thermo Fisher Scientific and Roche Diagnostics have expanded their portfolios by launching high-sensitivity PCR tests and rapid antigen kits, catering to both clinical and point-of-care settings. Regulatory bodies like the FDA have streamlined emergency use authorizations (EUAs) for at-home testing solutions, reflecting a shift toward decentralized diagnostics. Meanwhile, partnerships between diagnostic firms and public health agencies—such as LabCorp’s collaboration with the CDC—have bolstered global testing capacity. The sector has also witnessed strategic acquisitions, including DiaSorin’s purchase of a niche molecular diagnostics startup to enhance its viral detection capabilities. Enterprise demand has pivoted toward scalable, automated testing systems, while startups like DxTer have secured $50M in Series B funding to develop AI-driven diagnostic platforms. Forward-looking trends suggest sustained innovation in multiplexed testing and integration with digital health tools to address future outbreaks.

Analyst Overview

The monkeypox virus tests market exhibits strong market attractiveness driven by surges in outbreaks, heightened public health vigilance, and regulatory support for rapid diagnostics. Competitive intensity remains moderate, with a mix of established players and niche innovators leveraging molecular, antigen, and PCR-based testing technologies. The long-term outlook is cautiously optimistic, contingent on sustained funding for surveillance and vaccine-rollout-linked testing demands. The innovation landscape is dynamic, prioritizing point-of-care solutions, multiplex platforms, and AI-driven data analytics to enhance diagnostic accuracy. Demand–supply balance faces periodic strain during outbreak peaks, underscoring the need for scalable manufacturing and global distribution networks. Key risk factors include viral mutation rates impacting test efficacy, regulatory delays, and fluctuating funding post-pandemic. For stakeholders, strategic partnerships and R&D focus on next-gen sequencing could mitigate uncertainties in this evolving monkeypox virus tests market outlook.

11 items

1. Executive Summary

2. monkeypox virus tests Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global monkeypox virus tests Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global monkeypox virus tests Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals & Clinics

6.1.2. Diagnostic Laboratories

6.1.3. Others

6.2. Global monkeypox virus tests Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Polymerase Chain Reaction (PCR)

6.2.2. Lateral Flow Assay (LFA)

6.2.3. Others

6.3. Global monkeypox virus tests Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global monkeypox virus tests Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global monkeypox virus tests Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global monkeypox virus tests Market Competition by Key Manufacturers

8.1. Global monkeypox virus tests Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global monkeypox virus tests: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Aegis Sciences Corp.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Laboratory Corp. of America Holdings

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Quest Diagnostics, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sonic Healthcare Ltd.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. QIAGEN

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Mayo Clinic Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Chembio Diagnostics, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sonora Quest Laboratories

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Thermo Fisher Scientific

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. BD

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global monkeypox virus tests Market

Figure 4: Global monkeypox virus tests Market: Drivers

Figure 5: Global monkeypox virus tests Market: Challenges

Figure 6: Global monkeypox virus tests Market: Trends

Figure 7: Global monkeypox virus tests Market: Opportunity

Figure 8: Global monkeypox virus tests Market: Restraint

Figure 9: Global monkeypox virus tests Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global monkeypox virus tests Market Value (USD Million) By Region

Figure 15: Global monkeypox virus tests Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global monkeypox virus tests Market Value (USD Million) By Region

Figure 23: Global monkeypox virus tests Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global monkeypox virus tests Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global monkeypox virus tests Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global monkeypox virus tests Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global monkeypox virus tests Market Value (USD Million) By Region

Table 10: Global monkeypox virus tests Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global monkeypox virus tests Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global monkeypox virus tests Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global monkeypox virus tests Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Aegis Sciences Corp. Basic Information And Sales Area

Table 31: Aegis Sciences Corp.. Products Portfolio

Table 32: Laboratory Corp. of America Holdings Basic Information And Sales Area

Table 33: Laboratory Corp. of America Holdings. Products Portfolio

Table 34: Quest Diagnostics, Inc. Basic Information And Sales Area

Table 35: Quest Diagnostics, Inc.. Products Portfolio

Table 36: Sonic Healthcare Ltd. Basic Information And Sales Area

Table 37: Sonic Healthcare Ltd.. Products Portfolio

Table 38: QIAGEN Basic Information And Sales Area

Table 39: QIAGEN. Products Portfolio

Table 40: Mayo Clinic Laboratories Basic Information And Sales Area

Table 41: Mayo Clinic Laboratories. Products Portfolio

Table 42: Chembio Diagnostics, Inc. Basic Information And Sales Area

Table 43: Chembio Diagnostics, Inc.. Products Portfolio

Table 44: Sonora Quest Laboratories Basic Information And Sales Area

Table 45: Sonora Quest Laboratories. Products Portfolio

Table 46: Thermo Fisher Scientific Basic Information And Sales Area

Table 47: Thermo Fisher Scientific. Products Portfolio

Table 48: BD Basic Information And Sales Area

Table 49: BD. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global monkeypox virus tests Market Value (USD Million) By Region

Table 55: Global monkeypox virus tests Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

monkeypox virus tests Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	894.07 million
Growth rate	CAGR of 25% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Aegis Sciences Corp.; Laboratory Corp. of America Holdings; Quest Diagnostics, Inc.; Sonic Healthcare Ltd.; QIAGEN; Mayo Clinic Laboratories; Chembio Diagnostics, Inc.; Sonora Quest Laboratories; Thermo Fisher Scientific; BD
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options